Clinical significance of the 2016 WHO classification in Japanese patients with gliomas

Brain Tumor Pathology
Toshihiko IuchiMakiko Itami

Abstract

In this study, we retrospectively compared the prognostic value of the 2016 WHO classification with the former classification in 387 patients with glioma treated at our institution. According to the new classification, diagnoses included oligodendroglioma with isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion (5.4%), anaplastic oligodendroglioma with IDH mutation and 1p/19q co-deletion (3.4%), diffuse astrocytoma IDH-mutated (3.9%), anaplastic astrocytoma IDH-mutated (2.8%), glioblastoma IDH-mutated (7.8%), glioblastoma IDH-wildtype (58.4%), diffuse midline glioma H3 K27M mutation (2.6%), oligodendroglioma NOS (1.3%), anaplastic oligodendroglioma NOS (0.8%), diffuse astrocytoma IDH-wildtype (2.8%), and anaplastic astrocytoma IDH-wildtype (10.9%). The prognoses of IDH-mutated astrocytomas clearly varied according to tumor grade. However, we identified no survival difference between IDH-wildtype anaplastic astrocytomas and glioblastomas; additionally, these tumors showed similar gene expression profiles. After exclusion of those without 1p/19q co-deletion, patients with oligodendroglial tumors showed excellent survival regardless of tumor grade. Our evaluation of chromosomal aberrations suggests that the MAPK/PI3K pa...Continue Reading

References

Apr 15, 1994·International Journal of Cancer. Journal International Du Cancer·M J BelloJ A Rey
Oct 7, 2004·Cancer Research·Hiroko OhgakiPaul Kleihues
Mar 8, 2005·DNA Research : an International Journal for Rapid Publication of Reports on Genes and Genomes·Hisashi YamakawaOsamu Ohara
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Oct 6, 2006·Journal of Neuropathology and Experimental Neurology·Constance A GriffinKathleen M Murphy
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc SansonJean-Yves Delattre
Sep 10, 2009·Annual Review of Pathology·Candece L GladsonWei Michael Liu
Aug 31, 2016·Acta Neuropathologica·Emeline TabouretUNKNOWN For POLA Network
Apr 20, 2017·Neurologia Medico-chirurgica

❮ Previous
Next ❯

Citations

Jul 23, 2020·Neuropathology and Applied Neurobiology·J K PetersenB W Kristensen
Jun 19, 2021·Molecular and Clinical Oncology·María Fernanda RuizGermán R Perez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.